Matrikine cosmetic peptide blend (Pal-GHK and Pal-GQPR)
A topical cosmetic blend of two palmitoylated matrikine peptides, palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), formulated for collagen synthesis stimulation in cosmetic anti-aging applications.
Abstract
Matrixyl 3000 is a cosmetic ingredient blend developed by the French company Sederma (Croda) consisting of two palmitoylated matrikine peptides: palmitoyl tripeptide-1 (Pal-Gly-His-Lys; Pal-GHK; molecular weight approximately 578 Da; the palmitoylated version of the well-characterized matrikine GHK that is the basis of GHK-Cu, KDC-MN-007) and palmitoyl tetrapeptide-7 (Pal-Gly-Gln-Pro-Arg; Pal-GQPR; molecular weight approximately 619 Da). The matrikine concept describes short bioactive peptides released by enzymatic degradation of extracellular matrix proteins (collagens, elastin, laminin) that signal to dermal fibroblasts to repair the matrix; the matrikine signal is interpreted as a tissue-damage marker that drives compensatory matrix synthesis. GHK is the canonical collagen-promoting matrikine; the GQPR sequence is derived from immunoglobulin and inhibits IL-6-induced inflammatory cytokine production. The palmitoylation of both peptides anchors them in the lipid bilayer of the stratum corneum, substantially improving topical retention relative to the unmodified peptides and providing sustained cutaneous delivery. The pharmacological argument for the blend over either peptide alone is the dual mechanism: collagen synthesis stimulation through GHK signaling combined with anti-inflammatory and matrix-protective signaling through GQPR. Published manufacturer-sponsored studies report measurable increases in skin firmness, reduced wrinkle depth, and improved skin tone at 8 weeks of twice-daily topical application of 3 percent or 4 percent Matrixyl 3000 solutions. Independent academic replication is limited. The blend is sold as a cosmetic ingredient (not a regulated drug) in essentially all major cosmetic markets. Distinct from the original Matrixyl (palmitoyl pentapeptide-4, also known as Pal-KTTKS), which is a separate Sederma matrikine ingredient.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Synthetic cyclic octapeptide somatostatin analog with preferential somatostatin receptor subtype 2 and 5 agonism
A cyclic octapeptide somatostatin analog developed by Beaufour-Ipsen as the second clinically available long-acting somatostatin receptor ligand, distinguished by a unique self-assembling supersaturated depot formulation, antiproliferative activity in gastroenteropancreatic neuroendocrine tumors demonstrated in the landmark CLARINET trial, and a three-indication regulatory portfolio spanning acromegaly, neuroendocrine tumor growth control, and carcinoid syndrome.
Abstract
Lanreotide (D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; CAS 108736-35-2 free base; molecular formula C54H69N11O10S2; molecular weight 1096.33) is a synthetic cyclic octapeptide analog of native somatostatin-14, developed by Beaufour-Ipsen (now Ipsen) and introduced clinically in the early 1990s as the second somatostatin analog to reach the market after octreotide. The compound exhibits high-affinity agonism at somatostatin receptor subtypes 2 and 5 (SSTR2, Ki approximately 0.54 to 0.75 nM; SSTR5, Ki approximately 5.2 nM) with moderate affinity at SSTR3 and low affinity at SSTR1 and SSTR4, a selectivity profile that mediates suppression of growth hormone, insulin-like growth factor 1, and multiple gastrointestinal and pancreatic hormones through inhibition of adenylyl cyclase and reduction of intracellular cyclic adenosine monophosphate [1, 2]. The compound is formulated as lanreotide acetate in the Autogel (marketed as Somatuline Depot in the United States), a supersaturated aqueous gel in which lanreotide molecules self-assemble into hollow nanotubes of highly uniform diameter stabilized by beta-sheet hydrogen bonding, hydrophobic packing, and aromatic pi-pi stacking, producing a deep subcutaneous depot that releases active peptide over 28 days with a terminal elimination half-life of 23 to 30 days and absolute bioavailability of approximately 60 to 70 percent [3, 4]. The Autogel formulation, first approved in Europe in 2001 and in the United States in 2007, was the first marketed sustained-release pharmaceutical product produced by peptide self-assembly rather than by polymer microsphere encapsulation. Three indications are registered in the United States: long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and radiotherapy (FDA approved August 2007); treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival (FDA approved December 2014, on the basis of the CLARINET trial); and treatment of carcinoid syndrome in adults to reduce the frequency of rescue somatostatin analog therapy (FDA approved February 2018, on the basis of the ELECT trial) [5, 6, 7]. In acromegaly, lanreotide Autogel at 60 to 120 mg every 28 days normalizes growth hormone to below 2.5 micrograms per liter in approximately 58 percent and age-adjusted insulin-like growth factor 1 in approximately 48 percent of treatment-naive patients, with tumor volume reduction in approximately 60 percent of evaluated patients on long-term treatment [8, 9]. In the CLARINET trial, lanreotide 120 mg every 28 days versus placebo produced a hazard ratio for progression or death of 0.47 (95 percent confidence interval 0.30 to 0.73; P less than 0.001) in 204 patients with nonfunctioning, somatostatin-receptor-positive, grade 1 or 2 enteropancreatic neuroendocrine tumors, with estimated 24-month progression-free survival of 65.1 percent versus 33.0 percent [6]. In the ELECT trial, lanreotide 120 mg every 28 days significantly reduced the need for rescue short-acting octreotide for symptomatic carcinoid syndrome control and reduced patient-reported days with moderate or severe diarrhea and flushing [7]. The principal adverse events at registered doses are gastrointestinal (diarrhea 26 to 65 percent, abdominal pain 7 to 34 percent, nausea 5 to 11 percent), cholelithiasis and gallbladder sludge (14 to 20 percent), injection site reactions (5 to 22 percent), dysglycemia (hyperglycemia 5 to 14 percent, hypoglycemia 2 to 7 percent), and sinus bradycardia (3 to 8 percent) [10]. This monograph reviews the chemistry, synthesis, and self-assembly of lanreotide; the somatostatin receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record; the preclinical antiproliferative pharmacology; the clinical evidence base across acromegaly, neuroendocrine tumor, and carcinoid syndrome indications; reconstitution and handling; sourcing and quality verification; stack-interaction considerations; adverse-event signal; and a comparative assessment of five somatostatin receptor ligands against lanreotide on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Synthetic tetrapeptide bioregulator of pancreatic endocrine and exocrine cell differentiation and function
A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic modulator of pancreatic cell differentiation, glucose homeostasis, and beta cell functional recovery in aging and type 2 diabetes mellitus.
Abstract
Pancragen (Lys-Glu-Asp-Trp-NH2; KEDW) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (Russia) as a tissue-specific modulator of pancreatic endocrine and exocrine cell differentiation and function. The compound belongs to the Khavinson class of ultrashort (two to four amino acid) bioregulatory peptides, a pharmacological category defined by the hypothesis that short peptides penetrate cell nuclei, bind complementary DNA sequences in promoter regions through electrostatic and hydrogen-bond interactions, and modulate gene expression in a tissue-specific manner without engaging classical cell-surface receptors. Pancragen was derived from fractionation of bovine pancreatic tissue extracts; the tetrapeptide Lys-Glu-Asp-Trp was identified as the minimal active sequence responsible for the pancreotrophic activity of the parent extract preparation Suprefort. The compound has a molecular formula of C26H36N6O9 (free acid form) and a molecular weight of 576.60 g/mol. Physical-chemical characterization by ultraviolet-visible absorption spectroscopy, circular dichroism, and molecular modeling has demonstrated that the KEDW tetrapeptide binds double-stranded DNA in the major groove at sequences containing the ACCT motif, which is found in promoter regions of genes responsible for pancreatic cell differentiation and function [1]. The principal downstream molecular consequence of this interaction is upregulation of transcription factors that govern pancreatic endocrine cell fate, including PDX1 (the earliest marker of pancreatic progenitor cells and the master regulator of beta cell identity), NGN3, PAX6, PAX4, FOXA2, NKX2-2, and NKX6.1 [2, 3]. In organotypic pancreatic cell cultures from young and aged rats, Pancragen stimulated the expression of differentiation factors of both acinar cells (Pdx1, Ptf1a) and islet of Langerhans cells (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2), with the inducing effect more pronounced in aged cultures, consistent with a geroprotective mechanism [3]. Preclinical pharmacology in streptozotocin-induced diabetic rats demonstrated that oral Pancragen produced a pronounced hypoglycemic effect during the treatment period and that intramuscular administration normalized the adhesion properties of mesenteric capillary endothelium without modifying capillary permeability, suggesting homeostatic and endothelioprotective activity in early diabetes [4]. In a study of biological activity using immunoenzyme and high-performance liquid chromatography methods, the tetrapeptide modulated metabolic parameters characterizing apoptosis, including caspase-3 activity, in pancreatic beta cells and hepatocytes from streptozotocin-treated animals [5]. Primate studies in aged female rhesus monkeys demonstrated that a 10-day intramuscular course of Pancragen at 50 micrograms per day markedly increased the glucose disappearance rate, decreased basal insulin and C-peptide levels, and normalized glucose, insulin, and C-peptide dynamics during intravenous glucose tolerance testing, with partial persistence of these effects for three weeks after cessation of treatment [6, 7]. A comparative study in the same primate model demonstrated that Pancragen normalized insulin and C-peptide levels (suggesting recovery of disturbed glucose tolerance) while glimepiride produced a stronger but delayed blood-glucose-lowering effect without substantially affecting insulin secretion, indicating mechanistically distinct activity [7]. In a clinical study of 33 elderly patients with type 2 diabetes mellitus, Pancragen administered against a background of constant-dose glibenclamide significantly decreased fasting plasma glucose and glucose concentrations at two hours during oral glucose tolerance testing, reduced plasma insulin levels, and decreased the HOMA insulin resistance index; an additional glucose-lowering effect persisted for two weeks after cessation of Pancragen in 60 percent of patients who continued glibenclamide at unchanged doses [8]. Organotypic tissue culture studies confirmed that Pancragen at concentrations as low as 0.05 ng/mL stimulated tissue growth in pancreatic explants from both young and aged rats, with the stimulating effect tissue-specific (no effect on non-pancreatic tissue explants at the same concentration) [9]. The compound has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is marketed in Russia as a dietary supplement (Pancragen capsules) and is available internationally as a research-grade peptide from multiple suppliers. Formal toxicology studies meeting International Council for Harmonisation or FDA regulatory standards have not been published. The existing safety data, derived exclusively from the Khavinson research network, report no significant adverse events in preclinical or clinical studies at the doses and durations studied. This monograph reviews the chemistry, synthesis, and structural class of Pancragen; the epigenetic and transcriptional mechanism of action; the available pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology in cell culture, rodent, and primate models; the clinical evidence base in type 2 diabetes; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative pancreatic bioregulatory or beta cell-active compounds against Pancragen on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Synthetic tetrapeptide bioregulator with testicular tissue-specific epigenetic and steroidogenesis-modulating activity
A synthetic tetrapeptide (Lys-Glu-Asp-Gly) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the defined active sequence of the testicular polypeptide complex Testoluten, proposed to modulate steroidogenic gene expression and Leydig cell function through direct peptide-DNA interaction and chromatin remodeling in testicular endocrine tissue.
Abstract
Testagen, the synthetic tetrapeptide Lys-Glu-Asp-Gly (one-letter code KEDG; molecular formula C17H29N5O9; molecular weight 447.44), is a testicular-derived bioregulatory peptide synthesized and characterized by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (IBG) beginning in the early 2000s. The compound belongs to the Khavinson class of ultrashort (two to seven residue) peptide bioregulators, a family of synthetic sequences modeled on tissue-specific peptide fragments isolated from organ extracts by acid-pepsin hydrolysis and ultrafiltration, and is the defined synthetic analog of the active component of the testicular polypeptide complex preparation Testoluten [1, 2]. Testagen is distinguished within the Khavinson bioregulator family by a testicular tissue-directed pharmacological profile that centers on three proposed activities: first, modulation of steroidogenic gene expression in Leydig cells, with reported effects on expression of genes encoding steroidogenic acute regulatory protein (StAR), cholesterol side-chain cleavage enzyme (CYP11A1), 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD), and 17-beta-hydroxysteroid dehydrogenase, the principal rate-limiting enzymes in the testosterone biosynthetic cascade from cholesterol to testosterone [3, 4]; second, epigenetic modulation through direct peptide-DNA interaction and chromatin remodeling, consistent with the broader Khavinson hypothesis that ultrashort peptides act as sequence-specific regulators of gene expression through complementary electrostatic interactions with DNA in gene promoter regions [5, 6]; and third, normalization of hypothalamic-pituitary-gonadal (HPG) axis signaling in aged animal models, with reported restoration of luteinizing hormone receptor expression on Leydig cells and normalization of the testosterone-to-luteinizing hormone ratio [7, 8]. The compound shares the general Khavinson bioregulator mechanism of cell and nuclear membrane penetration, direct interaction with histone proteins and double-stranded DNA, and modulation of gene transcription, a framework supported by fluorescence microscopy tracking of labeled peptide analogs into cell nuclei and by electrophoretic mobility shift assays demonstrating peptide-DNA complex formation [5, 6]. Structurally, Testagen differs from the closely related Khavinson bioregulators Epithalon (Ala-Glu-Asp-Gly, pineal-derived), Livagen (Lys-Glu-Asp-Ala, liver-derived), and Cortagen (Ala-Glu-Asp-Pro, brain-derived) by single residue substitutions that are proposed to confer tissue-specificity through differential DNA sequence recognition [9]. The substitution of lysine at position 1 (versus alanine in Epithalon) and glycine at position 4 (versus alanine in Livagen) produces a distinct charge distribution and hydrogen-bonding pattern that molecular modeling studies have associated with preferential interaction with promoter sequences of testicular steroidogenic genes [5, 10]. No formal pharmacokinetic studies have been published for Testagen. The compound, as a linear tetrapeptide with unprotected termini, is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid, with a predicted plasma half-life on the order of minutes. No human clinical trials of the synthetic KEDG tetrapeptide have been registered on ClinicalTrials.gov or on major international trial registries. The clinical evidence base is limited to a single uncontrolled Russian-language clinical study and to ex vivo human cell studies. The parent polypeptide complex Testoluten has been used in Russian gerontological clinical practice for age-related testosterone decline and male subfertility, but the synthetic tetrapeptide does not hold separate pharmaceutical registration in any jurisdiction. Testagen is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is supplied as a research-grade lyophilized powder by multiple peptide suppliers at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Testagen; the proposed epigenetic, steroidogenic, and HPG axis mechanisms in molecular detail; the available pharmacokinetic considerations; the preclinical pharmacology across testicular aging and reproductive models; the limited clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five male reproductive or endocrine candidates against Testagen on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Synthetic immunomodulatory dipeptide bioregulator of thymic origin with epigenetic chromatin-remodeling activity
A synthetic dipeptide (L-Lys-L-Glu) derived from structural analysis of the thymic polypeptide complex Thymalin, developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the smallest bioactive peptide bioregulator with immunomodulatory, geroprotective, and epigenetic chromatin-reactivation activity in aging immune cells.
Abstract
Vilon (L-lysyl-L-glutamic acid; KE dipeptide; CAS 45234-02-4; molecular formula C11H21N3O5; molecular weight 275.30 g/mol) is a synthetic dipeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the minimal pharmacophore unit of the thymic polypeptide extract Thymalin. The compound represents the shortest bioactive peptide characterized in the Khavinson bioregulatory peptide class, consisting of a single lysine residue bonded to a single glutamic acid residue in the alpha-peptide linkage. Despite its minimal chain length, Vilon has demonstrated reproducible immunomodulatory, anti-tumor, geroprotective, and epigenetic activity across more than two decades of experimental investigation conducted primarily in Russian academic institutions and published in the Bulletin of Experimental Biology and Medicine, Biogerontology, Advances in Gerontology, and the International Journal of Molecular Sciences. The principal molecular mechanism, characterized by Lezhava, Khavinson, and Jokhadze in a series of cytogenetic studies from 2003 to 2023, is sequence-specific binding to the tetranucleotide motif TCGA in gene promoter regions, producing deheterochromatinization (decondensation of constitutive and facultative heterochromatin) in aging lymphocytes and thymocytes, with consequent reactivation of ribosomal genes and release of age-repressed transcriptional programs [1, 2, 3]. The immunomodulatory activity, characterized in thymic cell cultures and in the THP-1 monocyte/macrophage cell line, includes upregulation of CD4 and CD5 T-lymphocyte differentiation markers, enhancement of nucleolar organizer region associated protein expression, stimulation of interleukin-2 gene expression in blood lymphocytes, and suppression of lipopolysaccharide-induced tumor necrosis factor alpha and interleukin-6 release from terminally differentiated macrophages [4, 5, 6]. The geroprotective profile, established in female CBA mice receiving subcutaneous Vilon from 6 months of age through the lifespan, includes increased mean lifespan by approximately 24 percent, increased physical activity and endurance, decreased body temperature, and reduced incidence of spontaneous neoplasms including lung adenomas and lymphomas [7, 8]. Antitumor activity was independently confirmed in a chemically induced rat urinary bladder carcinogenesis model, where Vilon reduced tumor incidence from 75.5 percent to 56 percent and inhibited preneoplastic changes in the urothelial mucosa [9]. Clinical application in the Russian Federation, where Vilon has been used in investigational and observational settings for postoperative immune reconstitution, chronic infection management, geriatric immune support, and adjunctive diabetes mellitus management, has produced reports of insulin dose reduction (mean 9 units) in 150 patients with type 1 diabetes and favorable tolerability with no consistent adverse events across multiple cohort studies [10, 11, 12]. Pharmacokinetic data from intestinal tract and liver homogenate studies demonstrate that the KE dipeptide resists hydrolysis in small intestinal preparations and is only marginally degraded in large intestinal and hepatic preparations, supporting oral and parenteral bioavailability [13]. The compound is not approved by the United States Food and Drug Administration or by the European Medicines Agency. It is not registered as a pharmaceutical product outside the Russian Federation. Research-grade Vilon is supplied by multiple peptide synthesis vendors at greater than 98 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, synthesis, and structural characterization of Vilon; the epigenetic and immunomodulatory mechanisms in molecular detail; the pharmacokinetic data; the preclinical geroprotective and antitumor evidence; the clinical observational evidence; sourcing, reconstitution, and stack-interaction considerations; the adverse-event profile; and a comparative assessment of five thymic and immunomodulatory peptide bioregulators (Thymogen, Thymalin, Thymosin alpha-1, Thymulin, Epithalon) against Vilon on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Desflurane is the fully fluorinated successor to isoflurane and produces the fastest induction and emergence of any clinical volatile anesthetic, courtesy of the lowest blood-gas partition coefficient in the class (0.42). Approved in 1992 (Suprane). The high vapor pressure (it boils near room temperature) requires a special heated, pressurized vaporizer rather than the standard variable-bypass design. Hepatic metabolism is essentially negligible (under 0.02 percent), eliminating the fluoride and trifluoroacetylation concerns of older agents. The downsides: it irritates airways too much for inhalational induction, it triggers transient sympathetic surges with rapid concentration changes, and it has the highest global warming potential of the class (GWP100 around 2540, versus 130 for sevoflurane). Several health systems have restricted its use on environmental grounds. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Halogenated ether volatile general anesthetic
The fully fluorinated successor to isoflurane with the lowest blood-gas coefficient of any clinical volatile, enabling the fastest induction and emergence in the class.
Abstract
Desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl ether; CAS 57041-67-5; molecular formula C3H2F6O; molecular weight 168.04) is a fully fluorinated methyl ethyl ether developed by Ross Terrell at Anaquest in the 1980s and approved by the FDA in 1992 (Suprane). The minimum alveolar concentration (MAC) at age 40 is 6.0 percent in oxygen, the highest of the clinical volatile anesthetics; the blood-gas partition coefficient is 0.42, the lowest in the class, producing the fastest induction and emergence kinetics among approved inhalational agents. The high vapor pressure (664 mmHg at 20 degrees Celsius, near the boiling point of 23 degrees Celsius) requires a heated, pressurized vaporizer (Tec 6 or equivalent) rather than the variable-bypass design used for isoflurane and sevoflurane. Mechanism is the standard halogenated ether profile: GABA-A positive allosteric modulation, K2P channel activation, glycine and NMDA modulation. Hepatic metabolism is minimal (less than 0.02 percent of an absorbed dose), the lowest among inhalational anesthetics, virtually eliminating fluoride-related nephrotoxicity and trifluoroacetylated hepatotoxicity. The principal clinical limitations are airway irritation that precludes inhalational induction (coughing, breath-holding, laryngospasm at concentrations above 6 percent in non-anesthetized patients) and sympathetic stimulation with rapid concentration increases producing transient tachycardia and hypertension. The high MAC and high vapor pressure make desflurane the most expensive volatile per case at typical fresh gas flows, though low-flow techniques mitigate cost. Environmental concerns about high global warming potential (GWP100 approximately 2540 versus 130 for sevoflurane and 510 for isoflurane) have driven institutional restrictions on desflurane use in several health systems.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
Chloroprocaine (Nesacaine) is a 2-chloro analog of procaine introduced in the 1950s. The single chlorine substitution adjacent to the ester linkage dramatically accelerates plasma cholinesterase hydrolysis, producing the shortest plasma half-life of any clinical local anesthetic (roughly 21 seconds). That ultra-short systemic exposure makes chloroprocaine the safest local anesthetic for fetal exposure during obstetric epidural, and a useful agent for short-procedure spinal anesthesia in ambulatory surgical centers. The historical association with cauda equina syndrome traced to a sodium bisulfite preservative, not the drug itself; reformulation with EDTA and later preservative-free preparations resolved that concern, and chloroprocaine has returned to ambulatory spinal anesthesia as an alternative to lidocaine spinal (which carries its own transient neurologic symptoms concern). Maximum recommended doses are 11 mg/kg plain, 14 mg/kg with epinephrine. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Ester local anesthetic (very short-acting)
A 2-chloro-substituted procaine analog with the fastest plasma cholinesterase hydrolysis among local anesthetics, used in obstetric epidural and short-procedure spinal anesthesia.
Abstract
Chloroprocaine (2-(diethylamino)ethyl 4-amino-2-chlorobenzoate; CAS 133-16-4; molecular formula C13H19ClN2O2; molecular weight 270.76) is an ester-class local anesthetic introduced in the 1950s (Nesacaine) as a 2-chloro analog of procaine. The 2-chloro substitution adjacent to the ester linkage substantially accelerates plasma cholinesterase hydrolysis, producing the shortest plasma half-life of any clinical local anesthetic (approximately 21 seconds, versus 1 minute for procaine and far longer for amides). The very short systemic exposure makes chloroprocaine the safest local anesthetic for fetal exposure during obstetric epidural anesthesia and a useful agent for short-procedure spinal anesthesia in ambulatory surgical centers where rapid offset and discharge readiness are operationally valuable. Mechanism is voltage-gated sodium channel block with state-dependent kinetics; potency is similar to procaine on a milligram basis and substantially less than amide agents. The historical association with neurotoxicity (cauda equina syndrome) traces to the bisulfite preservative formulation used in Nesacaine through the 1980s and a high-pH, sodium bisulfite preservative system that produced free radical injury to nerve roots when administered intrathecally; reformulation with EDTA preservative and subsequent preservative-free 1 percent and 3 percent preparations resolved the neurotoxicity concern, and chloroprocaine has returned to spinal anesthesia use in ambulatory surgery as an alternative to lidocaine spinal (which carries its own transient neurologic symptoms concern). Modern formulations are preservative-free or use methylparaben preservatives at concentrations below the historical threshold for nerve injury. Maximum recommended doses are 11 mg/kg without epinephrine and 14 mg/kg with epinephrine.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
A serotonergic indolylcarboxylate ester developed at Sandoz as a chemotherapy-induced antiemetic, distinguished from other setrons by intrinsic partial agonist activity at the alpha-7 nicotinic acetylcholine receptor and downstream cognitive, anti-inflammatory, and analgesic activity.
Abstract
Tropisetron, the indol-3-carboxylate ester of tropine and the third selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist introduced for the management of chemotherapy-induced and postoperative nausea and vomiting, is a clinically marketed antiemetic in approximately 50 jurisdictions outside the United States and a research compound of escalating interest in cognition, central nervous system inflammation, fibromyalgia, and Alzheimer’s disease. Distinct from ondansetron and granisetron in pharmacology though not in marketed indication, tropisetron is a dual-mechanism agent: at the 5-HT3 ligand-gated cation channel it produces insurmountable, low-nanomolar antagonism with approximately 1000-fold selectivity over other monoamine receptors, while at the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor it acts as a potent partial agonist with low-micromolar functional activity in heterologous expression systems and in cortical and hippocampal neurons. The alpha-7 nicotinic activity, first formally characterized in the seminal Macor et al. (2001) report and subsequently extended by the Hashimoto laboratory in mouse models of phencyclidine-induced cognitive deficit and DBA/2 P50 auditory gating dysfunction, distinguishes tropisetron sharply from the other clinically marketed setrons and underwrites a research literature that now spans schizophrenia cognitive endpoints, fibromyalgia analgesia, refractory pruritus, ocular and pulmonary inflammation, postoperative neurocognitive recovery, and a Spilman et al. (2014) demonstration that tropisetron also binds the ectodomain of amyloid precursor protein at submicromolar affinity and normalizes cognition in the J20 transgenic mouse model of Alzheimer’s disease at a human-equivalent oral dose of approximately 5 mg per day. Pharmacokinetics in humans are dominated by hepatic CYP2D6-mediated ring hydroxylation, producing a striking polymorphic phenotype: in extensive metabolizers, the plasma elimination half-life after a 5 mg oral dose is approximately 5 to 8 hours, while in CYP2D6 poor metabolizers the half-life extends to 30 to 40 hours and steady-state plasma concentrations approach an order of magnitude greater on chronic dosing, a finding that has both safety and dose-response implications. The compound is well tolerated at registered doses; the principal short-term adverse events are dose-dependent constipation, headache, and transient hypertension, and rare clinically significant arrhythmia is captured in pooled postmarketing data and prescribing labels. This monograph reviews the chemistry, synthesis, and stereochemistry of tropisetron; the dual-receptor pharmacology in molecular and electrophysiological detail; the comprehensive human pharmacokinetic record including CYP2D6 polymorphism; the clinical evidence base across antiemetic, fibromyalgia, schizophrenia cognitive, Alzheimer’s disease, tinnitus, and inflammatory indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; and a comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against tropisetron on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antiemetic application; investigators should obtain analytical confirmation of identity and purity on every lot.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
A synthetic cyclic nonapeptide analogue of oxytocin developed by Ferring Pharmaceuticals as a selective tocolytic for the management of preterm labor, distinguished from beta-adrenergic and calcium channel blocker tocolytics by its uterine-specific mechanism of action and favorable maternal cardiovascular safety profile.
Abstract
Atosiban (1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin; CAS 90779-69-4; molecular formula C43H67N11O12S2; molecular weight 994.19 g/mol) is a synthetic cyclic nonapeptide analogue of oxytocin that functions as a competitive antagonist at the oxytocin receptor and at the vasopressin V1a receptor, developed by Ferring Pharmaceuticals in Sweden and first reported in the literature by Melin et al. in 1986 [1]. The compound is the only oxytocin receptor antagonist approved for clinical tocolytic use, registered in the European Union since January 2000 under the trade name Tractocile and subsequently approved in approximately 67 countries for the acute management of preterm labor in pregnant women between 24 and 33 completed weeks of gestation. Atosiban is not approved by the United States Food and Drug Administration or in Japan; the absence of United States registration reflects Ferring’s assessment that the FDA requirement for placebo-controlled trials in United States patients would be ethically untenable rather than a formal regulatory rejection on efficacy or safety grounds [2]. At the molecular level, atosiban inhibits oxytocin-mediated activation of the Gq/phospholipase C/inositol 1,4,5-trisphosphate signaling cascade in myometrial cells, reducing intracellular calcium release from the sarcoplasmic reticulum and diminishing calcium influx through voltage-gated channels, thereby suppressing uterine smooth muscle contraction [3, 4]. The compound additionally suppresses oxytocin-mediated prostaglandin E2 and prostaglandin F2-alpha release from decidual tissue, a secondary mechanism that contributes to the tocolytic effect. Receptor binding studies report moderate affinity for the oxytocin receptor (Ki approximately 397 nmol/L) and high affinity for the vasopressin V1a receptor (Ki approximately 4.7 nmol/L), with negligible affinity at the V1b and V2 vasopressin receptor subtypes [5]. The onset of uterine quiescence after intravenous administration is rapid, with significant reduction in contraction frequency within 10 minutes. Pharmacokinetics are characterized by an initial half-life of 0.21 hours and a terminal half-life of 1.7 hours after intravenous infusion, a volume of distribution of 18.3 liters, plasma protein binding of 46 to 48 percent in pregnant women, and predominantly peptidase-mediated metabolism that is independent of the cytochrome P450 system [6]. The standard clinical dosing regimen comprises a 6.75 mg intravenous bolus followed by a loading infusion of 300 micrograms per minute for 3 hours and a maintenance infusion of 100 micrograms per minute for up to 45 hours, with total treatment not exceeding 48 hours and total dose not exceeding 330.75 mg. Phase III clinical trials demonstrated that 59.6 percent of atosiban-treated women remained undelivered without alternative tocolysis at 7 days compared to 47.7 percent in the beta-agonist comparator arm, with maternal cardiovascular adverse events occurring approximately 10-fold less frequently in the atosiban group (8.3 percent versus 81.2 percent) [7, 8]. The compound is well tolerated; nausea is the most common adverse event at 14 percent, and no serious maternal safety signals have been identified across more than 156,000 treatment cycles in postmarketing surveillance through 2005. A secondary research application in assisted reproduction has emerged from the observation that atosiban-mediated reduction in uterine contractility during embryo transfer may improve implantation rates in in vitro fertilization, with meta-analyses reporting significantly higher clinical pregnancy rates in atosiban-treated groups compared to controls [9, 10]. This monograph documents the chemistry, synthesis, and peptide pharmacology of atosiban; the oxytocin receptor and vasopressin V1a receptor antagonism in molecular and functional detail; the comprehensive pharmacokinetic record; the clinical evidence base across tocolytic and assisted reproduction indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling protocols; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five alternative tocolytic agents (nifedipine, ritodrine, indomethacin, magnesium sulfate, terbutaline) against atosiban on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
A long-acting glycoprotein fusion of recombinant human growth hormone with three copies of the C-terminal peptide of human chorionic gonadotropin beta-subunit, engineered by OPKO Health and commercialized by Pfizer as a once-weekly subcutaneous injection for the treatment of pediatric growth hormone deficiency, distinguished from daily somatropin by its prolonged pharmacokinetic profile and from other long-acting growth hormone preparations by its CTP-based half-life extension platform.
Abstract
Somatrogon (somatrogon-ghla; CAS 1663481-09-1; approximate molecular weight 40 kDa including glycosylation) is a long-acting recombinant human growth hormone receptor agonist produced in Chinese hamster ovary cells by recombinant DNA technology and approved for the treatment of pediatric growth hormone deficiency as a once-weekly subcutaneous injection. The molecule comprises the complete 191-amino-acid sequence of native human growth hormone with one copy of the 28-amino-acid C-terminal peptide (CTP) from the beta-subunit of human chorionic gonadotropin fused at the N-terminus and two tandem copies of CTP fused at the C-terminus [1, 2]. The CTP cassettes introduce O-linked glycosylation sites that reduce renal clearance, extend the circulating half-life from the 2 to 4 hours of native somatropin to an effective half-life of approximately 28 to 38 hours, and thereby permit once-weekly dosing at 0.66 mg/kg without loss of growth-promoting efficacy relative to daily somatropin [3, 4]. Somatrogon binds the homodimeric growth hormone receptor and activates the JAK2-STAT5b signaling cascade, producing downstream increases in hepatic and peripheral insulin-like growth factor 1 (IGF-1) synthesis, skeletal longitudinal growth, protein anabolism, and modulation of carbohydrate and lipid metabolism identical in pathway to native growth hormone [5, 6]. The pivotal global Phase 3 clinical trial (NCT02968004) randomized 224 treatment-naive prepubertal children with growth hormone deficiency to once-weekly somatrogon (0.66 mg/kg) or once-daily somatropin (Genotropin, 0.24 mg/kg/week) for 12 months and demonstrated non-inferiority of somatrogon on the primary endpoint of annualized height velocity (somatrogon 10.12 cm/year versus somatropin 9.78 cm/year), with height standard deviation score improvements numerically favoring the somatrogon arm [7]. A parallel Phase 3 study in Japanese children confirmed non-inferiority with consistent safety [8]. Long-term extension data through 5 years of treatment demonstrated sustained catch-up growth with a mean height standard deviation score increase from baseline of 1.94 at extension year 4, consistent with durable efficacy [9]. The safety profile is characterized by injection site reactions (pain in 39.4 percent of somatrogon recipients versus 25.2 percent of somatropin recipients), nasopharyngitis, headache, pyrexia, and the pharmacological class effects of growth hormone therapy including transient hyperglycemia, hypothyroidism unmasking, and benign intracranial hypertension [7, 10]. Immunogenicity is notable: 77.1 percent of somatrogon-treated subjects developed anti-drug antibodies during the 12-month pivotal trial versus 15.6 percent of somatropin-treated subjects, but neutralizing antibody activity was not detected, and anti-drug antibodies did not have a clinically significant impact on efficacy or safety through 42 months of observation [7, 11]. Somatrogon received marketing authorization from the European Medicines Agency in January 2022, from Health Canada in December 2021, from the Australian Therapeutic Goods Administration in 2021, and from the United States Food and Drug Administration on June 27, 2023, following an initial complete response letter in January 2022 that required supplementary manufacturing data [12, 13]. The compound is marketed as Ngenla in a prefilled pen presentation requiring no reconstitution. This monograph reviews the molecular design, CTP-based half-life extension technology, growth hormone receptor pharmacology, comprehensive pharmacokinetic characterization, the pediatric clinical evidence base, sourcing and handling considerations, drug interaction profile, adverse event and immunogenicity data, and a structured comparative assessment of five alternative growth hormone preparations against somatrogon on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.
